Clinical trials: Retinal Vascular Disorder
Intraocular Inflammation, Retinal Vascular Occlusion
Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular Occlusion
This non-interventional descriptive study was undertaken to better understand the most common imaging features associated with inflammation arising in the post-marketing setting when brolucizumab was prescribed in routine…
- Trial name
- NCT05657158
- Testing
- Brolucizumab
- Where
- Switzerland
- Volunteers
- 198 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Retinal Vein Occlusion
Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Central and branch retinal vein occlusions are major causes of visual loss. Hemorrhage and capillary nonperfusion, when they involve the macula, can contribute to visual loss, but the major cause is macular edema.
- Trial name
- LVO (NCT00407355)
- Testing
- Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Peter A Campochiaro, MD
Wet Macular Degeneration
Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01249937)
- Testing
- Ranibizumab, Triamcinolone Acetonide
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that…
- Trial name
- NCT07308639
- Testing
- anti-VEGF medication
- Where
- Germany
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Macular Holes, Epiretinal Membrane
Intraoperative OCT Guidance of Intraocular Surgery II
The overall five-year goals of the project are to develop novel technology to provide actionable new information through provision of live volumetric imaging during surgery, improving surgical practice and outcomes.
- Conditions
- Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment
- Trial name
- MIOCT (NCT03713268)
- Testing
- Microscope integrated optical coherence tomography
- Where
- United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Duke University
Retinal Vein Occlusion
Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
This study seeks to compare dexamethasone implant with rescue intravitreal ranibizumab to monthly intravitreal ranibizumab for the treatment of macular edema secondary to branch or central retinal vein occlusion.
- Trial name
- NCT01581151
- Testing
- Dexamethasone intravitreal implant, Monthly Ranibizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brian Burke, MPH
Central Retinal Vein Occlusion
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
This study evaluates whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO).
- Trial name
- TRUST (NCT03981549)
- Testing
- Autologous Bone Marrow CD34+ Stem Cells
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The Emmes Company, LLC
Central Retinal Artery Occlusion
Early Reperfusion Therapy With Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion
Non-arteritic, thromboembolic central retinal artery occlusion (CRAO) is an acute neurovascular-ophthalmological emergency which leads to severe and permanent vision loss; no evidence-based therapy does exist.
- Trial name
- REVISION (NCT04965038)
- Testing
- Tenecteplase (until trial protocol V04: Alteplase)
- Where
- Germany
- Volunteers
- 127 people
- Sponsor
- University Hospital Tuebingen
Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
Macular neovascular diseases including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), pathological myopia (PM) and etc. can cause severe vision loss.
- Conditions
- Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, Pathological Myopia, Conbercept
- Trial name
- NCT03128463
- Testing
- Intravitreal injection of conbercept
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Xun Xu
Eye Diseases, Diabetes
Prophylactic PRP in Moderate NPDR
Diabetic retinopathy (DR) is a challenge to ophthalmic practice in communities with poor socioeconomic development. The COVID 19 pandemic has accentuated the challenge.
- Conditions
- Eye Diseases, Diabetes, Diabetic Retinopathy
- Trial name
- NCT05543564
- Testing
- PRP
- Where
- Egypt
- Volunteers
- 68 people
- Sponsor
- Assiut University
Proliferative Diabetic Retinopathy
The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT
The purpose of this study is to determine the threshold level of proliferative diabetic retinopathy progression and regression after standard panretinal photocoagulation.
- Trial name
- IMPETUS-D (NCT02157350)
- Testing
- Panretinal laser photocoagulation
- Where
- Denmark
- Volunteers
- 65 people
- Sponsor
- Odense University Hospital
Diabetic Macular Edema (DME)
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME).
- Trial name
- QUELL-DME (NCT07812090)
- Testing
- Oral BGE-102, Anti-VEGF
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- BioAge Labs, Inc.
Ischemia, Retinal Vein Occlusion
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
The RAVE 2 trial is a phase I, open label, 12-month trial of intravitreal ranibizumab 2.0 mg in patients with ischemic CRVO who have been either previously treated with ranibizumab or treatment naïve.
- Conditions
- Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases
- Trial name
- RAVE2 (NCT01225146)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- David M. Brown, M.D.
Vitreous Hemorrhage, Diabetic Retinopathy
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
- Trial name
- NCT00198497
- Testing
- Vitrase
- Where
- 58 sites in Australia, Brazil and 7 more
- Volunteers
- 510 people
- Sponsor
- Bausch & Lomb Incorporated
Diabetic Retinopathy
Comparison of Different Fluence Settings for Yellow Subthreshold Laser Treatment in Diabetic Macular Edema
To assess the safety and efficacy of two subthreshold parameters (5% and 15% duty cycle (DC)) compared to standard ETDRS (early treatment of diabetic retinopathy study) continuous wave (CW) laser
- Trial name
- NCT03571659
- Testing
- Laser
- Volunteers
- 32 people
- Sponsor
- L.V. Prasad Eye Institute
Diabetic Retinopathy, Diabetic Cataract
Pars Plana Vitrectomy Combined With Phacoemulsification Cataract Surgery in Phakic Diabetes Retinopathy Patients
Pars plana vitrectomy (PPV) is one of the most widely used surgical therapies to proliferative diabetic retinopathy in the world.
- Trial name
- NCT04729023
- Testing
- Pars plana vitrectomy combined with cataract surgery., Pars plana vitrectomy with subsequent cataract surgery.
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Diabetic Retinopathy
Self-testing Diagnosis Imaging Model for Diabetic Retinopathy
This is a prospective clinical study. At the Shaoguan Diabetic Eye Screening Programme, patients ages 30-80 will undergo the two diagnostic models: (1) in a remote diagnostic clinic site, patients undergo a self-testing device…
- Trial name
- NCT05223556
- Testing
- Full Self-Diagnostic device in a remote diagnostic imaging site, Human imager operated diagnostic device in the hospital
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Branch Retinal Artery Occlusion, Central Retinal Artery Occlusion
Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
Canadians fear loss of vision more than any other disability. Vision loss has an enormous impact on quality-of-life and is extremely costly from a societal and economic perspective.
- Conditions
- Branch Retinal Artery Occlusion, Central Retinal Artery Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
- Trial name
- NCT01348633
- Where
- Canada
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
- Trial name
- Super Tuscan (NCT07205887)
- Testing
- Remigromig, Aflibercept 2.0 mg
- Where
- 55 sites in United States
- Volunteers
- 160 people
- Sponsor
- EyeBiotech Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.